1 March 2006
	Newsletter

Solvo Biotechnology Announces Appointment of Dietrich Keppler to the International Scientific Advisory Board!

Solvo Biotechnology announced today the appointment of Professor Dietrich Keppler to its International Scientific Advisory Board. Professor Keppler is recognized as a global leader in the field of drug transporter science.

"We are extremely pleased and deeply honored to have such a world leading scientist as Professor Keppler join our International Scientific Advisory Board," said SOLVO's President and CEO Mr Ernő Duda.

Dietrich Keppler, M.D., is Professor of Tumor Biochemistry at the University of Heidelberg and Head of the Division of Tumor Biochemistry, German Cancer Research Center, Heidelberg. His scientific achievements include: the discovery of D-galactosamine-induced hepatitis; elucidation of mode of action of D-galactosamine; discovery of cell death in liver and hepatoma induced by uridine triphosphate deficiency and pyrimidine analogs; description of the metabolism, analysis, and transport of leukotrienes in vivo; description of the ATP-dependent transport across the hepatocyte canalicular membrane and mechanisms of cholestasis; the elucidation of the function of the multidrug resistance protein 1 (MRP1; symbol ABCC1) as a conjugate export pump and most recently the discovery, cloning, and characterization of the apical multidrug resistance protein MRP2 (symbol ABCC2) deficient in Dubin-Johnson syndrome as well as the cloning and localization of MRP3, MRP4, and MRP5; identification of MRP5 as export pump for the cyclic nucleotides and the cloning and characterization of uptake transporters of the OATP family. He has also been a leader in the generation of multiple-transfected polarized cells stably expressing OATP uptake transporters and MRP efflux pumps, as in vitro models for vectorial transport in hepatobiliary elimination and as tools in drug development.

Professor Keppler has received numerous awards and prizes including: Prix Galien Deutschland (Galenus award), together with W. Hagmann and C. Denzlinger, for research on the role of cysteinyl leukotrienes in endotoxin action (1985); Heinrich Wieland Prize for research on metabolism and analysis of leukotrienes (1987); Nagai Foundation Tokyo, Japan, Distinguished Lectureship and award for achievement in medical and pharmaceutical sciences (2002); Lucie Bolte Award of the German Association for the Study of the Liver (GASL) for achievements in research on liver diseases (2004) and the Fourth Nathan Kaufman distinguished Lectureship, awarded by Queens University, Faculty of Health Sciences, Ontario, Canada, for research on the molecular basis and pathobiology of transport into and out of the liver.

"Professor Keppler is regarded worldwide as a global opinion leader in the field of drug transporter science. We are very excited and look forward to working with him in the development and promotion of new drug transporter technologies that will help reduce the cost and time of drug development ," commented Dr. Peter Krajcsi, Chief Scientific Officer of Solvo Biotechnology.

About Solvo Biotechnology
Solvo Biotechnology - "The Transporter Company" has been the pioneer and the leader in the commercialization of Membrane Transporter technologies, including therapeutics, diagnostics and drug discovery assays. The company offers drug discovery products and services to pharmaceutical, biotechnology and consumer goods industries, relevant to many therapeutic areas and product categories. All major pharmaceutical and biotechnology companies use SOLVO's assays, either in-house, or as contracted research to significantly reduce the time and cost of the compound development process. By now, it is a common knowledge that efflux and various uptake transporters play key roles in the function of the Blood-Brain Barrier (BBB), the blood-CSF barrier, the blood-testis barrier, the intestinal epithelia (absorption), the airway epithelia, the liver epithelia and the kidney epithelia. SOLVO products can be used to study the transport properties of these pharmacological barriers. SOLVO's mainstream products are its High Throughput in vitro assay systems to detect the interaction of test compounds with a wide array of ABC Transporter proteins, and cell lines expressing various uptake transporter proteins used for in vitro ADME/Tox, oncology drug research and MDR modulating agent discovery. For additional information, please refer to the company's web site at www.solvo.com or call +36-23-503-937.

CONTACT:
Gábor Heltovics
Business Development Director
Solvo Biotechnology
+36-23-503-937

With our best regards,
SOLVO Biotechnology
Business Development Team

For Customers in Japan: Funakoshi (distributor of SOLVO membrane products) Iwaki (exclusive distributor of SOLVO Fee-for Service Screenings, distributor of SOLVO membrane products)

Privileged/confidential information may be contained in this message. This communication is confidential and intended solely for the addressee(s). Unauthorized distribution, modification or disclosure of the contents may be unlawful. If you receive this in error, please notify the sender and delete it from your system. If you are not the addressee indicated in this message (or responsible for delivery of the message to such person), you may not copy or deliver this message to anyone.

If you wish to unsubscribe, please send a letter to with 'unsubscribe' in the subject field.